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Background: Solid organ transplant recipients are particularly vulnerable for infectious diseases due to prolonged
immunosuppressive treatment. Residents of endemic regions and travellers may be exposed to malaria and may,
therefore, require prolonged antimalarial chemoprophylaxis. The hypothesis of this study was that certain
immunosuppressive drugs may exert clinically relevant anti-malarial activity. It was therefore designed to assess the
intrinsic anti-malarial activity of everolimus, mycophenolic acid, and rapamycin against Plasmodium falciparum in an
in vitro model.
Methods: Three laboratory adapted clones of P. falciparum and two isolates were used to assess the potential of
mycophenolic acid, rapamycin and everolimus to inhibit in vitro growth of P. falciparum. The standard histidine rich
protein 2 assay was employed and inhibitory drug concentrations (IC) were computed by non-linear regression analysis.
Results: All drugs were associated with complete inhibition of P. falciparum growth in in vitro assays. Mycophenolic acid
demonstrated IC50 and IC90 values of 5.4 μmol/L and 15.3 μmol/L. Rapamycin inhibited P. falciparum growth at
7.2 μmol/L (IC50) and 12.5 μmol/L (IC90), respectively. Finally, everolimus displayed IC50 and IC90 values of 6.2
μmol/L and 11.5 μmol/L. There was no difference in in vitro activity against chloroquine sensitive or chloroquine
resistant parasites.
Conclusions: All immunosuppressive drugs evaluated in this in vitro study demonstrated activity against
P. falciparum. Inhibitory concentrations of mycophenolic acid are within clinically achievable plasma
concentrations when used in solid organ transplant recipients. Further in vivo evaluation of mycophenolic acid
either alone or in combination regimens may prove promising for the concomitant prevention of P. falciparum in
solid organ transplant recipients living or travelling in malaria endemic regions.
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Despite international efforts to control and ultimately elim-
inate malaria, Plasmodium falciparum remains among the
three most deadly infectious pathogens in sub-Saharan
Africa causing an estimated 627,000 deaths every year [1].
One of the most formidable challenges in the fight against
falciparum malaria is the ongoing emergence and spread of
drug resistant isolates leading to reduced efficacy and ef-
fectiveness of established anti-malarial therapies [2]. Large-* Correspondence: michael.ramharter@medizin.uni-tuebingen.de
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unless otherwise stated.scale in vitro screening of drug candidates is performed to
discover new compounds with anti-malarial activity [3].
However, only a fraction of those with proven in vitro activ-
ity are successfully developed to a marketed drug mostly
due to concerns with safety and tolerability in preclinical or
clinical development. Screening of drugs already used in
clinical practice for other indications than malaria is an-
other valuable approach to build-up the anti-malarial arma-
mentarium. Drugs which are used for chronic conditions
necessitating lifelong treatment may be of particular inter-
est for their use as anti-malarial prophylactic agents.
The ever growing number of patients requiring im-
munosuppressive therapy after solid organ transplantation
is particularly vulnerable for infectious diseases. Whereasl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cyclosporine A have been shown to exhibit anti-malarial
activity in vitro, no conclusive data are available for
everolimus and mycophenolic acid – two of the most
widely used immunosuppressive drugs [4]. An immuno-
suppressive combination treatment with collateral
prophylactic efficacy against malaria would constitute
an important benefit for solid organ transplant recipi-
ents in malaria endemic regions and travellers to trop-
ical countries. This would be of even higher clinical
benefit as immunosuppressive drugs are prone to clinic-
ally significant drug interactions and the interaction of
anti-malarials and immunosuppressive drugs is cur-
rently not well understood. This study was, therefore,
designed to assess the in vitro activity of mycophenolic
acid, everolimus and rapamycin against P. falciparum to
obtain further information about the potential of cur-
rently used immunosuppressives as anti-malarial
prophylactic drugs.
Methods
Laboratory strains and clones
The study was performed with three P. falciparum clones
with distinct anti-malarial resistance patterns (Dd2, 3D7
and 7G8) and two laboratory-adapted strains from return-
ing travellers. Clones Dd2 and 7G8 are resistant against
chloroquine, whereas 3D7 sensitive to all commonly used
anti-malarials [5]. Laboratory adapted strains originated
from two returning travellers who acquired P. falciparum
infections in West Africa. These strains demonstrate high
level resistance against chloroquine but are sensitive
against mefloquine and artemisinin derivatives. Parasites
were kept in continuous malaria culture as described pre-
viously [6].
Test compounds
Chloroquine diphosphate salt (Sigma, C6628) was
dissolved in double distilled water. Mycophenolic acid
(Fluka, 70018), rapamycin (Sigma, R0395) and everoli-
mus (Fluka, 07741) were dissolved in absolute ethanol.
All stock solutions were further diluted in double distilled
water to obtain respective target concentrations. 96-wellTable 1 Individual IC50 and IC90 values for respective immuno
sample and for chloroquine resistant strains, respectively
Individual IC50 and IC90 values
1
3d7 7G8 Dd2
IC50 IC90 IC50 IC90 IC50 IC90
Mycophenolic acid 5.3 15.1 5.4 15.3 5.7 16.7
Rapamycin 8.1 12.5 6.7 11.8 6.6 12.3
Everolimus 7.5 11.8 5.1 10.7 6.4 11.5
Chloroquine 0.01 0.03 0.19 1.05 0.22 1.09
1 in μmol/L, 2 Chloroquine resistant, 3 interquartile range.culture plates were coated with ascending concentrations
of chloroquine (0.003-3 μmol/L), mycophenolic acid (0.6-
39 μmol/L), rapamycin (0.2- 13.7 μmol/L) and everolimus
(0.2-13 μmol/L). Test plates were dried and kept at 4°C for
a maximum of two weeks before use. All drug assays were
performed in duplicate with all P. falciparum clones and
strains.Drug sensitivity assay
Cultured parasites were incubated for 72 hours on pre-
coated plates and drug sensitivity assays were performed
using an ELISA for quantitative measurement of the P. fal-
ciparum specific histidine rich protein 2 (HRP-2). ELISA
plates were coated with commercial monoclonal antibodies
and tests were performed as previously described [7]. An at
least four-fold increase in HRP-2 concentrations was set as
threshold for further statistical analysis of drug sensitivity
assays. Statistical analysis was performed and inhibitory
concentrations (IC) were calculated using freely available
software [8]. This program was developed to analyse data
from malarial drug sensitivity tests such as the HRP-2
assay and produces non-linear regression models to calcu-
late individual inhibitory concentrations (IC). No ethical
clearance was required for this in vitro study following reg-
ulations of the Ethics Committee of the Medical University
of Vienna.Results
Immunosuppressives
All drugs were tested in parallel against the three clones
and two strains of P. falciparum resulting in 20 evaluable
drug-concentration/growth-inhibition curves. Growth rates
were sufficient in all assays for further analysis. Mycophe-
nolic acid led to complete inhibition of in vitro growth of P.
falciparum at 19.5 μmol/L and 39 μmol/l, respectively.
Complete growth inhibition was achieved at highest con-
centrations of rapamycin (13.7 μmol/L) and at 13 μmol/L
of everolimus for all tested clones and isolates. Individual
50 and 90 percent inhibitory concentrations are shown in
Table 1.suppressive drugs are shown for each tested parasite
Median IC50 and IC90 values
Strain 1 Strain 2 CQr2 parasites
IC50 IC90 IC50 IC90 IC50 IC90
5.4 14.4 6.4 23.7 5.6 (5.4-5.9)3 16 (15.1-18.5)
7.2 12.7 7.8 12.7 6.9 (6.6-7.4) 12.5 (12.2-12.7)
5.8 11.2 6.2 11.6 6 (5.7-6.3) 11.3 (11.1-11.5)
0.21 0.65 0.27 0.73 0.21 (0.2-0.23) 0.9 (0.7-1.1)
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immunosuppressive drugs
As shown by the individual IC values in Table 1, 3D7
was the only chloroquine sensitive parasite tested in this
trial. Median results for chloroquine resistant parasites
are presented in comparison and no consistent pattern
of alterations in anti-malarial activity of immunosup-
pressive drugs in chloroquine resistant versus chloro-
quine sensitive parasite samples was observed.Discussion
Mycophenolic acid, rapamycin and everolimus reliably
inhibited in vitro growth of P. falciparum in our study. In-
hibition was independent of chloroquine susceptibility and
was observed in all tested parasites. Therapeutic target
concentrations are in the range of around 5.4-32.8 nmol/L
for rapamycin and 3–15.7 nmol/L for everolimus when
used as immunosuppressive drugs after solid organ trans-
plantations [9]. As the in vitro growth inhibition is at con-
siderably higher concentrations, these drugs are unlikely
to exert clinically important anti-malarial activity in vivo.
On the contrary, inhibitory concentrations for mycophe-
nolic acid were within clinically relevant plasma levels in
patients using standard immunosuppressive regimens for
solid organ transplantation. Peak plasma levels after oral
intake of 1 g mycophenolic acid are around 78 μmol/L
[10]. Importantly, mycophenolic acid has a relatively long
half-life of around 17 hours leading to sustained high
plasma concentrations in currently recommended twice
oral daily regimens. Trough levels under steady state con-
ditions are around 10 μmol/L indicating the potential for
prolonged anti-malarial in vitro activity of mycophenolic
acid [11]. With all caveats applicable for extrapolation of
in vitro data to the in vivo situation, these results clearly
demonstrate the potential of clinically important activity
of mycophenolic acid against P. falciparum. Although this
drug is unlikely to be used as a targeted treatment for mal-
aria, its clinical usefulness as prophylactic agent in trans-
plant recipients may be further investigated. It may be
speculated that the use of mycophenolic acid alone – or in
combination with other immunosuppressive drugs – may
provide sufficient blood schizontocidal activity to preclude
the need for additional chemoprophylaxis.
Interestingly, there is a historic link of anti-malarials and
immunosuppressive drugs with the 4-aminoquinolines as
the most prominent example. Chloroquine – first devel-
oped as anti-malarial drug – has known immuno-
modulatory effects and is used on a large scale for the
treatment of rheumatic diseases including lupus erythema-
tosus [12]. Similarly, cyclosporine A and FK506 possess
antiparasitic activity and have been considered as lead
agents for new classes of antimicrobial drugs [13]. Myco-
phenolic acid may, therefore, become yet another exampleof an immunosuppressive drug with potentially clinically
important anti-malarial activity.
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